Health Care/Hospital
SyntheticGestalt and Enamine to Collaborate on the Creation of AI-Based Model to Facilitate Drug Discovery
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates. This model will utilize 38 billion compounds from Enamine REAL database as a dataset for pre-training. TOKYO and KYIV, Ukraine, Jan. 11, 2024 /PRNewswire/ -- SyntheticGestalt, a research and ...
2024-01-11 16:00
1569
Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a commercial stage global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that Dr.Dajun Yang, the company's ...
2024-01-11 11:53
4631
Robooter Showcases Innovative Power Wheelchair X40 at CES 2024
LAS VEGAS, Jan. 10, 2024 /PRNewswire/ -- Robooter, a leading autonomous mobility device manufacturer renowned for its robotic technology supporting the elderly and disabled, is proud to present the innovative power wheelchair X40 and offer a new space and mobility solution through its partners at...
2024-01-11 01:00
1388
New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA
HONG KONG, Jan. 10, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine
Drug Development
2024-01-10 16:50
1808
LOTTE BIOLOGICS Announces Songdo Bio Plant Development Plan at JPM Healthcare Conference 2024
* Richard Lee, CEO of LOTTE BIOLOGICS, delivers a keynote speech at the JPM Healthcare Conference for the second consecutive year * Unveils company's bio plant development plan in Songdo to meet clients' needs SEOUL, South Korea, Jan. 9, 2024 /PRNewswire/ -- LOTTE BIOLOGICS (CEO Richard Lee) ...
2024-01-10 08:55
1496
Toratani Co., Ltd. Unveils Groundbreaking "Virtuous Circulation Pillow and Mattress" with Patented Technology for Enhanced Deep Breathing Experience
New sleeping solutions that facilitate deeper breathing, improve sleep quality, and bring health benefits TOKYO, Jan. 9, 2024 /PRNewswire/ -- Toratani Co., Ltd. (Kahoku City, Ishikawa Prefecture,Japan) has announced the launch of their innovative Toratani Virtuous Circulation Mattress and Pillow...
2024-01-09 21:00
1251
Baopu Development Joins IWBI's WELL for Residential Program
To help catalyze and spur leadership in health and well-being across the residential sector,Baopu Development is participating in a first-of-its-kind program aimed at establishing IWBI's new global standard for healthier and more resilient homes TAIPEI and NEW YORK, Jan. 9, 2024 /PRNewswire/ -- ...
2024-01-09 16:32
1306
Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock code ：688176.SH) has announced its set-up of the Women's Health Business Unit for commercialization. This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women'...
2024-01-09 12:25
1615
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib（ABSK021） has been granted orphan drug designation（ODD） by the European Medicines Agency (EMA) for the treatm...
2024-01-09 08:30
1424
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, b...
2024-01-08 22:00
5074
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap
HONG KONG, Jan. 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced thatMichelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the Company's achievements in the development of new bispecific a...
2024-01-08 21:38
1406
Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 (TROP2 ADC)
- First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024 NEWARK, Del. and NANJING, China, Jan. 8, 2024 /PRNewswire/ -- The Partner ...
2024-01-08 19:35
1172
So-Young Announces Update on Repurchase and Cancellation of Shares
BEIJING, Jan. 8, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that during the term of the Co...
2024-01-08 19:00
4575
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
* The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S. * The site is expected to employ 250 people when fully operational. WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Resea...
2024-01-08 17:52
4388
Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum's Disease
NEW TAIPEI CITY, Jan. 8, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the United States Food and Drug Administration (U.S. FDA) has accepted the CBL-514 Investigational New Drug (IND) application of CBL-0202 DD Phase 2 Study to treat Dercum's Disease. Dercum's disease...
2024-01-08 13:25
2134
Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis
- Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales. - Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worl...
2024-01-08 07:00
1441
Nuvilab Innovates Inpatient Nutrition with Food AI at Alexandra Hospital Singapore
SEOUL, South Korea, Jan. 5, 2024 /PRNewswire/ -- Nuvilab, a leading Food AI company, has announced the expansion of its healthcare services by providing a Nutrition Management Solution for Inpatients at Alexandra Hospital. This solution uses an AI Food Scanner to scan each patient's meal tray and...
2024-01-05 22:46
2745
Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
HONG KONG, Jan. 5, 2024 /PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab(开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxaliplatin (XEL...
2024-01-05 21:00
5693
Grant of Restricted Share Units to Mr. Xing Jin
BEIJING, Jan. 5, 2024 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that the Compensation Committe...
2024-01-05 19:00
6126
SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease
* Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights forGreater China and Singapore * Transaction reflects the Novartis commitment to the Chinese market and complements existing pipeline in renal diseases. SHANGHAI, Jan. 5, 2024 /PRNewswire/ -- San...
2024-01-05 16:00
2493
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5902
